Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide.
• Cisplatin is a widely used chemotherapeutic agent for NSCLC, but acquired resistance limits its clinical effectiveness.
• MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play critical roles in cancer development and treatment response.

Purpose of the Study:

• To investigate the functional role of miR-1244 in cisplatin-treated NSCLC.
• To elucidate the underlying molecular mechanisms by which miR-1244 influences cisplatin sensitivity in NSCLC cells.
• To explore the potential of miR-1244 as a biomarker for predicting treatment response and patient survival in NSCLC.

Main Methods:

• Quantitative PCR (qPCR) was used to assess miR-1244 expression levels in NSCLC cell lines and patient tissues.
• Cell viability, lactate dehydrogenase (LDH) release, and apoptosis assays were performed to evaluate the impact of miR-1244 modulation on cisplatin treatment.
• Western blotting was employed to analyze the protein expression of key apoptosis-related factors (caspase-3, p53, Bax) and cell cycle regulators (cyclin D1, MEF2D).
• Small interfering RNA (siRNA) targeting MEF2D was used to confirm its role in miR-1244-mediated effects.

Main Results:

• miR-1244 expression was significantly downregulated in cisplatin-treated NSCLC cell lines and patient tissues compared to untreated controls.
• Overexpression of miR-1244 in NSCLC cells enhanced cisplatin-induced cytotoxicity, suppressed cell viability, and promoted apoptosis.
• miR-1244 upregulation increased caspase-3 activity and the expression of p53 and Bax, while decreasing MEF2D and cyclin D1 protein levels.
• Knockdown of MEF2D using siRNA mimicked the effects of miR-1244 overexpression, confirming its involvement in the observed phenotypes.
• High miR-1244 expression correlated with superior overall survival in cisplatin-treated NSCLC patients.

Conclusions:

• miR-1244 plays a crucial role in sensitizing non-small cell lung cancer to cisplatin treatment.
• The tumor-suppressive function of miR-1244 in this context is mediated through the regulation of the MEF2D pathway, impacting apoptosis and cell proliferation.
• miR-1244 represents a potential therapeutic target and predictive biomarker for improving cisplatin chemotherapy outcomes in NSCLC patients.